NCT04962867View on ClinicalTrials.gov

NCCH2006/MK010 Trial (FORTUNE Trial)

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Advanced or Recurrent Solid TumorsFGFR Gene Alterations
Interventions
DRUG

E7090

140 mg of E7090 is orally administered once daily.

Trial Locations (7)

104-0045

RECRUITING

National Cancer Center Hospital, Chuo-ku, Tokyo

241-8515

RECRUITING

Kanagawa Cancer Center, Yokohama

980-8574

RECRUITING

Tohoku University Hospital, Aoba-ku, Sendai, Miyagi

812-8582

RECRUITING

Kyushu University Hospital, Higashi-Ku, Fukuoka

060-8648

RECRUITING

Hokkaido University Hospital, Kita-Ku, Sapporo, Hokkaido

700-8558

RECRUITING

Okayama University Hospital, Okayama

606-8507

RECRUITING

Kyoto University Hospital, Sakyo-ku, Kyoto

All Listed Sponsors
collaborator

Eisai Co., Ltd.

INDUSTRY

lead

National Cancer Center, Japan

OTHER_GOV